Hopp til innhold
NHI.no
Annonse

Temporalarteritt: Prognosen

Innhold i artikkelen

Langtidsutsiktene er gode dersom tilstanden behandles. Blindhet er en komplikasjon til AT, men synsproblemer kan i de fleste tilfeller unngås ved tidlig igangsatt behandling. 

Behandlingen er langvarig. De fleste behøver kortisonbehandling minimum et helt år. Noen får tilbakefall etter at medisinen avsluttes og må starte på ny med behandling enda et år. Enkelte vil trenge behandling kanskje opptil fem år med lave doser kortison.

Annonse

Både ved PMR og AT er det viktig å kontakte lege straks ved hodepine, synsproblemer eller andre tegn til temporalarteritt. Betennelse i tinningpulsåren kan unntaksvis oppstå selv om kortisonpreparater brukes. 

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Polymyalgia rheumatica . Referanselisten for dette dokumentet vises nedenfor

  1. Tengesdal S, Diamantopoulos AP, Brekke LK, et al. Polymyalgia rheumatica. Nasjonal veileder i revmatologi. Sist oppdatert 21.01.2025. metodebok.no
  2. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008 Jul 19;372(9634):234-45. doi: 10.1016/S0140-6736(08)61077-6. PMID: 18640460 PubMed
  3. Buttgereit F, Dejaco C, Matteson EL, et al.. polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 2016;315:2442–58. PMID: 27299619 PubMed
  4. González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet. 2017 Oct 7;390(10103):1700-1712. Epub 2017 Jul 31. PMID: 28774422. PubMed
  5. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014 Jul 3;371(1):50-7. PMID: 24988557. PubMed
  6. Rosenberg H, Halman S, Yadav K. Polymyalgia rheumatica. CMAJ. 2021 Nov 22;193(46):E1770. PMID: 34810164 PubMed
  7. Ezeonyeji AN, Borg FA, Dasgupta B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol. 2011;30(2):259–262.
  8. Gran JT, Myklebust G. Incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis. Rheumatology 2000; 39: 283-7. Rheumatology
  9. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010; 49: 186-90. Rheumatology
  10. Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 2010;62(12):3768–3775.
  11. González-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep. 2015 Feb;17(2):6. PMID: 25618572 PubMed
  12. Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology 2015. DOI: 10.1212/WNL.0000000000001409 DOI
  13. Liozon E, Parreau S, Filloux M, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review. Autoimmunity Reviews 2021. pubmed.ncbi.nlm.nih.gov
  14. Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 65: 943-54. www.ncbi.nlm.nih.gov
  15. Macchioni P1, Boiardi L, Catanoso M, Pazzola G, Salvarani C. Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 2014; 73: 1190-3. pmid:24297384 PubMed
  16. Ozen G, Inanc N, Unal AU, et al. Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study. J Rheumatol 2016. pmid:26834222 PubMed
  17. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford). 2010;49(4):716–722.
  18. Breuer GS, Nesher G. What does imaging tell us about polymyalgia rheumatica? Rheumatology 2011; 51: 5-6. Rheumatology
  19. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015; 74(10): 1799-807. Pmid: 26359488.
  20. Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. pmid: 27706804 PubMed
  21. Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate. Sist revidert juni 2015. www.uptodate.com
  22. Marsman DE, den Broeder N, van den Hoogen FHJ, et al. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol 2021. doi:10.1016/S2665-9913(21)00245-9 DOI
  23. Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy A Randomized Clinical Trial. JAMA 2022; 328: 1053-62. pmid:36125471 PubMed
  24. Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med 2023 Oct 5; 389:1263. PMID: 37792612 PubMed
  25. Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal cohort study. J Rheumatol 2015; 42:1213. doi: 10.3899/jrheum.141347 DOI
  26. Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, Maradit-Kremers H, Hutchings A, Matteson EL, Schirmer M; International Work Group for PMR and GCA. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2011;70:447–453
  27. Wu J, Keeley A, Mallen C et al. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ 2019; 191: E680-8. pmid:31235489 PubMed
  28. Faurschou M, Ahlstrom MG, Lindhardsen J, et al. Risk of Diabetes mellitus among patients diagnosed with giant cell arteritis or granulomatosis with polyangiitis: Comparison with the general population. J Rheumatol. 2016 . PMID:27744394 PubMed
  29. Narváez J, Estrada P, López-Vives L, et al.. Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica. Semin Arthritis Rheum. 2015 Dec;45(3):328-33. doi: 10.1016/j.semarthrit.2015.06.009. Epub 2015 Jun 19. PMID: 26186807 PubMed
  30. De Miguel E, Macchioni P, Conticini E, Campochiaro C, Karalilova R, Monti S, Ponte C, Klinowski G, Monjo-Henry I, Falsetti P, Batalov Z, Tomelleri A, Hocevar A. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology (Oxford). 2024 Jan 4;63(1):158-164. doi: 10.1093/rheumatology/kead189. PMID: 37129541 PubMed
  31. Hancock AT, Mallen CD, Muller S, et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014 Jul 28.
  32. Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart 2016. doi:10.1136/heartjnl-2015-308514 DOI
  33. Dasgupta B, Borg FA, Hassan N, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–190.
Annonse
Annonse